Understanding which patients and hospital care pathways affect outcomes after ICU vs ward care for ARF and sepsis
Official title: Identifying patient subgroups and processes of care that cause outcome differences following ICU vs. ward triage among patients with acute respiratory failure and sepsis
Funded at University of Pennsylvania · NIH-11372276 · Data updated 2026-11-12
A big study using hospital records to figure out which patients with acute respiratory failure and sepsis do best when admitted to ICUs versus general wards.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $711,362 |
| NIH project number | 5R01HL166269-04 |
| Project ID | NIH-11372276 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute respiratory failure and sepsis whose triage decisions between ICU and ward care could impact outcomes.
✕Less likely to help
Patients whose care pathways are not ICU-versus-ward dependent or whose data do not fit identified subgroups may see no clear benefit.
What this research studies
This project will analyze detailed electronic health record data from multiple health systems to identify patient subgroups and care processes that influence mortality and length of stay when ARF and sepsis patients are admitted to ICUs versus wards. By expanding the dataset to include more than 100 additional data fields per patient from 2013–2022, researchers aim to map patterns that lead to better or worse outcomes. The goal is to generate actionable insights that could guide triage decisions and optimize resource use in acute care settings. Results could inform future guidelines and targeted improvements in critical care pathways for ARF and sepsis patients.
Why it matters
Potential benefit: If successful, the findings could help hospitals triage ARF and sepsis patients more effectively, potentially reducing deaths and shortening hospital stays.
How similar studies have gone: Prior work showed significant differences in mortality and length of stay based on triage decisions, suggesting potential for impactful refinements.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Anesi, George L — University of Pennsylvania
- Study coordinator: Anesi, George L
Related research
Other NIH-funded projects on the same topics.
-
Understanding how care decisions affect outcomes for patients with breathing problems and sepsis
This project looks at hospital records to understand how decisions about where patients with severe breathing issues and sepsis receive care affect their recovery.
-
Understanding the risks of acute respiratory failure in patients with hospital-onset sepsis
This study looks at how patients with hospital-onset sepsis might face different chances of developing breathing problems, and it aims to find better ways to treat those at higher risk so they can get the care they need to feel better.
-
Understanding why critically ill patients with respiratory failure and sepsis face health disparities.
This study is looking into why critically ill patients with breathing problems and infections, especially those from minority backgrounds, often have worse health outcomes, and it aims to find ways to improve their care based on their unique challenges.
-
Understanding how ICU and ward care affects patients with severe respiratory issues and sepsis
This study looks at how choosing to treat patients with serious breathing problems and infections in either intensive care units or regular hospital rooms affects their recovery, with the aim of finding ways to improve care for these patients.
-
Using Ganciclovir to Prevent Cytomegalovirus Reactivation in Patients with Severe Respiratory Issues
This study is looking at whether the antiviral medication ganciclovir can help prevent the reactivation of cytomegalovirus (CMV) in adults with severe respiratory failure caused by sepsis, to see if it can improve their recovery and reduce the time they spend on a ventilator and in the ICU.
-
Using ganciclovir to stop cytomegalovirus from reactivating in patients with severe respiratory failure and sepsis
This study is looking at whether the antiviral drug ganciclovir can help prevent a virus called cytomegalovirus (CMV) from coming back in adults who are seriously ill with respiratory failure from sepsis, and it’s for people who want to help improve treatment options for patients in critical condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.